Immunex Message Board - Msg: 1587038

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Charles Hill who wrote (67)	6/13/1997 11:16:00 AM
From: Charles Hill	of 656

FYI: NEW YORK, June 12 (Reuter) - Alex Brown said on Thursday it raised its raised its 12-month target on Immunex Corp to $40 per share from $35 per share, after the company presented new positive data on its drug Enbrel. Immunex said on Tuesday that Enbrel, a TNF Receptor that can be used to treat rheumatoid arthritis, was shown to be safe in a multi-center retreatment study. ``These positive, longer-term data support our belief that Enbrel will be a major new treatment for rheumatoid arthritis, a billion-dollar commercial opportunity,'' Alex Brown analyst Kevin Tang said in a research note.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next